Interestingly, enrichment of the BTK-L528W mutation was observed in CLL patients receiving zanubrutinib compared to ibrutinib in observational studies, suggesting the potential for cross-resistance with reversible BTK inhibitors [113]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.